Skystar Bio-Pharmaceutical Company Stock

SKBI

US8308843007

Biotechnology & Medical Research

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

20/12/15	Skystar Bio Pharmaceutical Company(NasdaqCM:SKBI) dropped from NASDAQ Composite Index	CI
15/11/14	Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Fiscal 2014	CI

Valuation: Skystar Bio-Pharmaceutical Company

Market Cap	36.7M 32M 30.14M 27.45M 51.46M 3.52B 51.53M 361M 139M 1.79B 138M 135M 5.78B	P/E 2012	1.93x	P/E 2013	2.56x
Enterprise Value	39.2M 34.18M 32.19M 29.32M 54.96M 3.76B 55.03M 386M 149M 1.91B 147M 144M 6.17B	EV / Sales 2012	0.2x	EV / Sales 2013	0.69x
Free-Float	100%	Yield 2012 *	-	Yield 2013	-

* Estimated data More valuation ratios

Latest news: Skystar Bio-Pharmaceutical Company

20/12/15	Skystar Bio Pharmaceutical Company(NasdaqCM:SKBI) dropped from NASDAQ Composite Index	CI
15/11/14	Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Fiscal 2014	CI
14/11/14	Skystar Bio Mulls Acquisitions	CI
26/08/14	Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014	CI
15/08/14	Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for the 2014	CI
16/07/14	Skystar Bio Pharmaceutical Mulls Acquisitions	CI
08/07/14	Skystar Launches Bovine Immunoglobulin G Kits in China	CI
16/05/14	Skystar Bio Pharmaceutical Company Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reaffirms Revenue Guidance for the Year 2014	CI
01/04/14	Skystar Bio-Pharmaceutical Company Announces Consolidated Earnings Results for the Year Ended December 31, 2013; Provides Revenue Guidance for the Year 2014	CI
04/12/13	Skystar Bio Mulls Acquisitions	CI
15/11/13	Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Reiterates Earnings Guidance for the Fiscal 2013	CI
14/08/13	Skystar Bio Pharmaceutical Company Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2013; Reiterates Earnings Guidance of 2013	CI
16/05/13	Skystar Bio Pharmaceutical Company Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2013; Reiterates Revenue Guidance for the Year 2013	CI

More news

Managers and Directors: Skystar Bio-Pharmaceutical Company

Director	Title	Age	Since
Cheng Tun Qu BRD	Director/Board Member	60	01/07/2008

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SKYSTAR BIO-PHARMACEUTICAL COMPANY	-.--%	-.--%	-	-	0
LONZA GROUP AG	+0.59%	+3.31%	+1.03%	+24.53%	46.28B
IQVIA HOLDINGS INC.	+1.43%	+1.50%	+43.56%	+35.38%	43.85B
REVOLUTION MEDICINES, INC.	+1.13%	-5.93%	+334.47%	+533.04%	40.93B
BEONE MEDICINES AG	+4.28%	+3.44%	+8.34%	+94.90%	39.89B
CELLTRION, INC.	+1.11%	+1.80%	+11.52%	+43.15%	29.5B
MEDPACE HOLDINGS, INC.	+1.80%	+4.71%	+25.17%	+158.89%	17.09B
ASCENDIS PHARMA A/S	+0.33%	-10.47%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+2.12%	+10.41%	+24.78%	+39.05%	15.22B
TEMPUS AI, INC.	+0.32%	+24.92%	-9.50%	-	14.05B
Average	+1.31%	+3.57%	+54.92%	+132.70%	26.24B
Weighted average by Cap.	+1.58%	+2.08%	+68.85%	+141.22%

See all sector performances

Skystar Bio-Pharmaceutical Co., Ltd. is a manufacturer and distributor of veterinary medicines and healthcare products in China. The Company develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Company operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives. The Company provides a range of veterinary products serving regional micro-farms offering, such as Veterinary vaccines, including aquaculture, Veterinary medicines, Pro-biotic microorganisms and Animal feed additives. The Company's Veterinary drug products include Ivermectin Premix, Feizhu San, Tilmicosin Premix, Stimulated egg powder, Wulingsan, Yimu Shenghua San, Qingwen Baidu San and Spectinomycin Hydrochloride Injection.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
SKBI Stock

-40%: Exceptional extension

SEIZE THE OFFER!

	2012	2013
Net sales	33.59M 29.28M 27.58M 25.12M 47.09M 3.22B 47.15M 330M 127M 1.64B 126M 123M 5.29B	42.48M 37.04M 34.89M 31.77M 59.57M 4.07B 59.64M 418M 161M 2.07B 160M 156M 6.69B
Net income	6.21M 5.42M 5.1M 4.65M 8.71M 595M 8.72M 61.1M 23.55M 303M 23.34M 22.82M 978M	10.53M 9.18M 8.65M 7.88M 14.76M 1.01B 14.78M 104M 39.91M 514M 39.55M 38.68M 1.66B
Net Debt	-5.61M -4.89M -4.61M -4.19M -7.86M -537M -7.87M -55.16M -21.26M -274M -21.07M -20.6M -883M	2.5M 2.18M 2.05M 1.87M 3.5M 239M 3.51M 24.57M 9.47M 122M 9.38M 9.18M 393M

Skystar Bio-Pharmaceutical Company Stock

Stocks

SKBI

US8308843007

Biotechnology & Medical Research

Valuation: Skystar Bio-Pharmaceutical Company

Latest news: Skystar Bio-Pharmaceutical Company

Managers and Directors: Skystar Bio-Pharmaceutical Company

Other Biotechnology & Medical Research

Financials

Company Profile